HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): James Huang Nabil P. Rizk Manjit S. Bains Robert J. Downey Raja M. Flores Bernard J. Park Valerie W. Rusch Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huang, J. Articles by Rusch, V. W. Search for Related Content PubMed Articles by Huang, J. Articles by Rusch, V. W. Related Collections Mediastinum Related Article

J Thorac Cardiovasc Surg 2007;134:1477-1484
© 2007 The American Association for Thoracic Surgery

General Thoracic Surgery

Feasibility of multimodality therapy including extended resections in stage IVA thymoma

^a Thoracic Service, Department of Surgery, Memorial Sloan–Kettering Cancer Center, New York, NY
^b Department of Pathology, Memorial Sloan–Kettering Cancer Center, New York, NY
^c Biostatistics Service, Department of Epidemiology–Biostatistics, Memorial Sloan–Kettering Cancer Center, New York, NY.

Read at the Eighty-seventh Annual Meeting of The American Association for Thoracic Surgery, Washington, DC, May 5-9, 2007.

Received for publication April 25, 2007; revisions received July 20, 2007; accepted for publication July 26, 2007.

^_* Address for reprints: Nabil P. Rizk, MD, Thoracic Service, Department of Surgery, Memorial Sloan–Kettering Cancer Center, 1275 York Ave, New York, NY 10021. (Email: rizkn{at}mskcc.org).

Objective: Extended resections for advanced-stage thymomas are not commonly performed because of the potential morbidity in the face of unclear survival or palliative benefit. We reviewed our experience with multimodality treatment for Masaoka stage IVA thymomas for feasibility and outcomes.

Methods: We conducted a retrospective review of a single-institution surgical database. Data included patient demographics, preoperative staging and treatment, perioperative events, pathologic findings, and postoperative outcomes.

Results: During the period from 1996 to 2006, 18 patients who had Masaoka stage IVA thymoma underwent surgical resection. All patients received preoperative chemotherapy. Four patients with extensive pleural involvement underwent concomitant extrapleural pneumonectomy and postoperative hemithoracic radiation. Complete resection was achieved in 12 (67%) patients. There was no operative mortality. With a median follow-up of 32.2 months (range 1.4–129.9 months), 3-year, 5-year, and 10-year survivals were 91%, 78%, and 65%, respectively, and median survival has not yet been reached.

Conclusion: Multimodality therapy including extended surgical resection can be performed in select patients with stage IVA thymoma with low morbidity and mortality and can result in excellent long-term survival.

Related Article

Discussion
J. Thorac. Cardiovasc. Surg. 2007 134: 1483-1484. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				J. Huang, G. J. Riely, K. E. Rosenzweig, and V. W. Rusch Multimodality Therapy for Locally Advanced Thymomas: State of the Art or Investigational Therapy? Ann. Thorac. Surg., February 1, 2008; 85(2): 365 - 367. [Full Text] [PDF]